文献速递认知障碍与痴呆帕金森病与运动障碍

AD与DLB混合病理的神经心理特征与认知轨迹

Neuropsychological Profile and Cognitive Trajectories of Patients With Biomarker Evidence of Alzheimer Disease or Dementia With Lewy bodies.
PubMed 文献 · Neurology · 2026-07-01

该回顾性纵向研究纳入350例记忆门诊患者,分为AD alone、AD伴α-突触核蛋白病理、DLB alone和DLB伴AD病理四组。基线时AD组记忆和语言损害重于DLB组;混合病理组在注意/处理速度、视空间记忆、执行功能等方面表现更差。纵向随访显示AD组记忆和语言下降快于DLB组,混合病理患者呈现不同认知轨迹。

要点

  • AD患者基线记忆和语言损害重于DLB患者。
  • AD伴α-突触核蛋白病理者注意/处理速度和观念运动性失用更差。
  • DLB伴AD病理者视空间记忆、结构性运用和执行功能更差。

核心结论

  • AD和DLB在体混合病理呈现不同的神经心理特征和认知轨迹。
  • 识别混合病理对准确诊断、预后评估和临床试验分层有临床意义。

研究设计与样本

  • 回顾性纵向研究,纳入学术记忆门诊队列350例参与者,基线有脑脊液和血液样本并完成全面认知评估。
  • 分组:AD alone n=249,AD伴α-突触核蛋白病理 n=31,DLB alone n=33,DLB伴AD病理 n=37。

主要发现

  • 基线AD患者记忆和语言损害重于DLB患者(均p<0.01)。
  • AD伴α-突触核蛋白病理者视觉注意/处理速度(F[1,259]=7.71,p<0.01)和观念运动性失用(F[1,244]=4.02,p<0.05)差于AD alone。
  • DLB伴AD病理者视觉记忆(F[1,38]=5.38,p<0.05)、结构性运用(F[1,59]=6.26,p<0.01)和执行功能(F[1,40]=5.68,p<0.05)差于DLB alone。
  • 纵向AD组记忆(β=0.184,SE=0.069,p<0.01)和语言(β=0.206,SE=0.074,p<0.01)下降快于DLB组。
  • AD伴α-突触核蛋白病理者编码(β=-0.186,SE=0.075,p<0.05)和延迟总回忆(β=-0.178,SE=0.082,p<0.05)下降更快。

关键数值与推荐

  • 血浆磷酸化tau217在AD患者中广泛与多个认知域较差表现相关(p<0.05)。
  • 混合病理患者中,原发AD诊断者记忆(β=-0.324,SE=0.104,p<0.01)、语言(β=-0.359,SE=0.109,p<0.01)和视空间功能(β=-0.356,SE=0.175,p<0.05)下降更显著。

临床怎么用

  • 记忆门诊中应结合脑脊液和血浆生物标志物识别AD与DLB混合病理。
  • 对混合病理患者需针对性评估注意/处理速度、视空间记忆和执行功能等认知域。
  • 认知轨迹差异有助于预后判断和临床试验患者分层。

局限性

  • 回顾性研究设计,样本来自单中心学术记忆门诊,混合病理亚组样本量较小。
  • 基线认知比较采用协方差分析控制年龄、性别和教育,纵向采用线性混合效应模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Alzheimer disease (AD) and dementia with Lewy bodies (DLB) often coexist, yet the cognitive effect of mixed AD and α-synuclein pathology in vivo remains unclear. We aimed to (1) characterize baseline neuropsychological profiles, (2) assess plasma biomarker associations, and (3) examine longitudinal cognitive trajectories in patients with AD, DLB, and mixed pathology in a memory clinic cohort. METHODS: This was a retrospective longitudinal study including participants from an academic memory clinic cohort with available CSF and blood samples at baseline who completed a comprehensive cognitive assessment. Baseline neuropsychological performance was compared between groups using analysis of covariance controlling for age, sex, and education. Associations between plasma biomarkers and cognition were examined using multiple linear regression models. Linear mixed-effects models examined longitudinal change across groups, with time from baseline, diagnosis, the diagnosis-by-time interaction, baseline age, sex, and years of education as fixed effects, and intercept as a random effect. RESULTS: A total of 350 participants (mean age 70.1 ± 6.6 years; 48.6% female) were included: AD alone (n = 249), AD with α-synuclein pathology (n = 31), DLB alone (n = 33), and DLB with AD pathology (n = 37). At baseline, patients with AD showed greater impairment than those with DLB in memory and language (all p < 0.01). Compared with AD alone, patients with AD and α-synuclein pathology showed poorer performance in visual attention/processing speed (F[1,259] = 7.71, p < 0.01) and ideomotor apraxia (F[1,244] = 4.02, p < 0.05). Conversely, patients with DLB and AD pathology performed worse than those with isolated DLB in visual memory (F[1,38] = 5.38, p < 0.05), constructional praxis (F[1,59] = 6.26, p < 0.01), and executive function (F[1,40] = 5.68, p < 0.05). Memory (p < 0.01) and language (p < 0.05) best differentiated groups with mixed pathology. Plasma phosphorylated tau at threonine 217 was broadly associated with worse performance across cognitive domains in patients with AD (p < 0.05). Longitudinally, patients with AD showed steeper decline than those with DLB in memory (β = 0.184, SE = 0.069, p < 0.01) and language (β = 0.206, SE = 0.074, p < 0.01). Within AD, those with α-synuclein pathology exhibited steeper decline in encoding (β = -0.186, SE = 0.075, p < 0.05) and delayed total recall (β = -0.178, SE = 0.082, p < 0.05). Among mixed-pathology patients, those with primary AD diagnosis showed greater decline across memory (β = -0.324, SE = 0.104, p < 0.01), language (β = -0.359, SE = 0.109, p < 0.01), and visuospatial function (β = -0.356, SE = 0.175, p < 0.05). DISCUSSION: Distinct neuropsychological profiles and trajectories emerge in AD and DLB depending on underlying pathology. Identifying mixed pathology in vivo is clinically relevant for accurate diagnosis and prognosis and has implications for outcome measures and patient stratification in clinical trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Tort-Merino A, Esteller-Gauxax D, Pérez-Millan A, et al. Neuropsychological Profile and Cognitive Trajectories of Patients With Biomarker Evidence of Alzheimer Disease or Dementia With Lewy bodies. Neurology. 2026. PMID: 42385111. doi:10.1212/WNL.0000000000218201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。